期刊
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
卷 61, 期 2, 页码 325-336出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/10408398.2020.1731678
关键词
Proprotein convertase subtilisin; kexin type 9; cardiovascular disease; nutraceuticals; inflammatory markers; LDL-cholesterol
PCSK9 is a protease that increases LDLR degradation, leading to elevated LDL-cholesterol levels. Antibodies targeting PCSK9 can lower LDL-cholesterol, while nutraceuticals and anti-inflammatory agents are beneficial for treating dyslipidemia.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease which increases the lysosomal degradation of low density lipoprotein receptor (LDLR) resulting in elevated serum LDL-cholesterol levels. Elevated LDL-cholesterol is the main risk factor for cardiovascular disease (CVD). Antibodies to PCSK9 decrease LDL-cholesterol. Recent studies have suggested a direct relationship between PCSK9 and inflammation and the potential inhibitory effects of anti-inflammatory agents against this enzyme. Nutraceuticals are natural compounds, which have numerous anti-inflammatory and lipid-lowering effects. In this review we focus on anti-inflammatory substances and nutraceuticals, which are beneficial in treatment of dyslipidemia. We also reviewed the recent findings concerning the role of PCSK9 as the main target for molecular mechanisms of these substances.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据